Covid-19: what are the side effects of the third dose?

Compartir : Facebook Twitter Whatsapp

A recent study conducted in Israel revealed possible side effects that may be associated with injecting a third dose, including shortness of breath. In many countries it has recently been indicated that a third dose of the covid-19 vaccine will be necessary.

Especially immunosuppressed people will benefit from a third dose of the Covid-19 vaccine as these patients are more prone to acute forms of the infection.

Pfizer vaccine: an Israeli study observed side effects of the third dose

Some countries have already started administering the third dose to their citizens. This is particularly the case in Israel, which has injected people aged 60 and over for ten days to slow the spread of the Delta variant. At the moment, 240,000 people are affected by this injection.

We know that vaccines can cause side effects. In a new study, broadcast by Reuters, Israeli scientists looked at side effects that may be associated with the administration of a third dose of the Pfizer / BioNTech vaccine. About 4,500 people who received it between July 30 and August 1 participated in the research by answering a questionnaire.

Pain at the injection site is still the most common side effect.

According to the results, 88% of the volunteers felt the same or even better after the injection of the third dose compared to the administration of the second dose. Almost 31%, however, mentioned pain at the injection site. This report is the most common and usually appears during the hours or days after vaccination.

However, more intense side effects have been reported. About 0.4% of the participants said they suffered from shortness of breath and 1% requested drug treatment to alleviate one or more side effects.

These "baseline" and "self-reported" results allow "comparing side effects with the second dose. In a large majority, they are similar or less important with the boost," according to Ran Balicer, head of the study and director of the Clalit Research Institute. "Although we do not yet have long-term studies on the effectiveness of the third booster dose for risk management in people older than 60 years, these results demonstrate the benefit of vaccination. They also emphasize the importance of prudent behavior among adults. , including limiting meetings indoors, "he said.

Compartir : Facebook Twitter Whatsapp